$141.96 0.7%
NVO Stock Price vs. AI Score (Last 150 days)
Data gathered: June 22

AI Score

Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Novo Nordisk

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents.

Novo Nordisk
Price $141.96
Target Price Sign up
Volume 3,020,000
Market Cap $644B
Year Range $92.83 - $143.63
Dividend Yield 0.97%
PE Ratio 49.78
Revenue per Employee $4,806,419
Industry Drug Manufacturers

In the news

Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '2465.3B9.92B55.4B25.4B35.3B5.680
Q4 '2365.9B10B55.8B22B28.5B4.910
Q3 '2358.7B9.71B49B22.5B32.8B5.000
Q2 '2354.3B7.86B46.4B19.4B26.7B17.410
Q1 '2353.4B8.18B45.2B19.8B27.6B8.780

Insider Transactions View All

No recorded Insider transactions.

Congress Trading View All

Politician Filing Date Type Size
Michael McCaul
May 17, 24 Buy $100K - $250K
Michael McCaul
May 17, 24 Buy $50K - $100K
Michael McCaul
May 17, 24 Buy $50K - $100K

What is the Market Cap of Novo Nordisk?

The Market Cap of Novo Nordisk is $644B.

What is Novo Nordisk's PE Ratio?

As of today, Novo Nordisk's PE (Price to Earnings) ratio is 49.78.

How Many People Work at Novo Nordisk?

As of our latest update, Novo Nordisk employed approximately 50,816 people worldwide. However, it's important to note that Novo Nordisk's workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Novo Nordisk's revenue per employee?

$4,806,419. To calculate Novo Nordisk's revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Novo Nordisk?

Currently, the price of one share of Novo Nordisk stock is $141.96.

How can I analyze the NVO stock price chart for investment decisions?

The NVO stock price chart above provides a comprehensive visual representation of Novo Nordisk's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Novo Nordisk shares. Our platform offers an up-to-date NVO stock price chart, along with technical data analysis and alternative data insights.

Does NVO offer dividends to its shareholders?

Yes, Novo Nordisk (NVO) offers dividends to its shareholders, with a dividend yield of 0.97%. This dividend yield represents Novo Nordisk's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Novo Nordisk in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.

What are some of the similar stocks of Novo Nordisk?

Some of the similar stocks of Novo Nordisk are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.